Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended July 31, 1997.
Status: Development Stage Enterprise. The company is in the pre-clinical trial stage of its products and has not commenced principal operations. It faces substantial doubt regarding its ability to continue as a going concern due to accumulated losses and a working capital deficit.
Key Financial Metrics
| Metric | Three Months Ended July 31, 1997 | Accumulated Since Inception |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(214,107) | $(8,501,239) |
| Net Loss Per Share | $(0.01) | $(0.01) |
| Cash and Equivalents (End of Period) | $15,877 | N/A |
| Working Capital Deficit | $(727,487) | N/A |
| Total Current Liabilities | $764,789 | N/A |
| Stockholders' Equity (Deficit) | $(496,619) | $(496,619) |
| Shares Outstanding | 42,829,500 | 42,829,500 |
Cash Flow Summary (Three Months Ended July 31, 1997):
- Net cash used in operating activities: $(109,699)
- Net cash used in investing activities: $(7,281)
- Net cash provided by financing activities: $79,000
Material Changes vs. Prior Period
- Research & Development Expenses: Decreased to $46,365 from $106,215 in the prior year quarter. This reduction was attributed to a significant decrease in research personnel, animal purchases, and supplies.
- General & Administrative Expenses: Increased to $167,064 from $126,575 in the prior year quarter. The increase was driven by higher legal fees, filing fees, and costs associated with foreign patent applications.
- Net Loss: Improved slightly to $(214,107) from $(234,008) in the prior year quarter, primarily due to the reduction in R&D spending.
- Liquidity: Cash balances decreased from $53,857 at the end of the prior fiscal year (April 30, 1997) to $15,877 at July 31, 1997.
Outlook, Risks, and Contingencies
Going Concern: The filing explicitly states that the company's continuation is dependent on generating sufficient cash flow, meeting obligations, and obtaining additional financing. There is no assurance that FDA approval will be granted or that funding will be secured.
Capital Needs: Significant additional financing is required to complete development and testing through Phase I, II, and III human trials. Management is pursuing strategic alliances and joint ventures.
Legal Contingencies: The company is involved in two pending legal matters filed by former employees regarding a temporary layoff in December 1995. Management estimates the exposure at $124,000, which has been accrued.
Commitments: Employment agreements with officers and employees include aggregate future commitments of $240,000 for 1998.
Investor Verification Checklist
- Capital Adequacy: Verify the company's ability to secure the significant additional financing required to proceed with clinical trials given the current cash balance of only $15,877.
- Going Concern Status: Assess the risk of insolvency given the working capital deficit of $727,487 and accumulated deficit of over $8.5 million.
- Legal Exposure: Confirm the status of the pending litigation and whether the $124,000 accrual remains sufficient.
- Regulatory Path: Evaluate the timeline and probability of FDA approval for pre-clinical products, noting the explicit lack of assurance in the filing.
- Stock Dilution: Review recent financing activities (including stock issuance for services and convertible debentures) to understand potential dilution to the 42.8 million outstanding shares.